Quick Answers: GLP-1 Side Effects
Most-asked questions about GLP-1 medication side effects — with answers based on published prescribing information.
The most commonly reported GLP-1 side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain or discomfort. Fatigue, headache, reduced appetite, and indigestion are also reported. Side effects vary by medication, dose, medical history, and individual response. Review the prescribing information for your specific medication and discuss any concerns with a licensed clinician.
Duration varies between patients and medications. Gastrointestinal side effects are most commonly reported early in treatment or in the days following a dose change. Some patients find side effects diminish over time; others experience persistent effects. Do not adjust your dose, skip doses, or stop treatment based on side effects without first talking with your prescriber or a licensed clinician.
All GLP-1 and dual GLP-1/GIP medications share a similar gastrointestinal side effect profile. Wegovy and Ozempic contain semaglutide; Zepbound and Mounjaro contain tirzepatide. The side effect profiles overlap significantly, but each medication has its own prescribing information with specific reported rates and warnings. Wegovy and Zepbound are FDA-approved for chronic weight management; Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Indications and approved uses are not the same.
Hair loss has been reported by some patients taking GLP-1 medications. The available evidence suggests it may be related to rapid weight loss (a condition known as telogen effluvium), nutritional changes, caloric restriction, or underlying health factors — rather than a direct pharmacological effect of the medication itself. If you are experiencing hair loss while on a GLP-1 medication, discuss it with your prescriber.
Seek prompt medical attention if you experience severe or persistent abdominal pain (especially upper abdominal pain), persistent vomiting, signs of dehydration (dark urine, dizziness, markedly reduced urination), symptoms of an allergic reaction (rash, hives, swelling, difficulty breathing), yellowing of the skin or eyes, rapid heartbeat, or any symptoms that feel severe, sudden, or unusual. This is not a complete list — always refer to your medication's prescribing information and consult your clinician.
No. Compounded GLP-1 preparations are not FDA-approved, and fewer reported side effects does not indicate greater safety. The FDA has raised concerns about compounded GLP-1 products, including risks of dosing errors, inconsistent potency, and misleading marketing. Compounded semaglutide is not a generic version of Ozempic or Wegovy. Compounded tirzepatide is not a generic version of Mounjaro or Zepbound. See our compounded GLP-1 guide for details.
Common GLP-1 Side Effects
The table below summarizes side effects that appear across GLP-1 prescribing information. This is not a complete list — each medication has its own full prescribing information. "When to contact a clinician" guidance is general; your prescriber's advice for your specific situation takes priority.
| Side Effect | Description | When to Contact a Clinician |
|---|---|---|
| Nausea | Most frequently reported GLP-1 side effect. Often appears early in treatment or after a dose change. | If severe, persistent, or prevents you from maintaining adequate fluid intake. |
| Vomiting | May accompany nausea. Generally less common than nausea alone. | If persistent, repeated, or you cannot keep fluids down. |
| Diarrhea | GI motility effects can cause loose stools. May alternate with constipation in some patients. | If severe, prolonged, or accompanied by signs of dehydration. |
| Constipation | Commonly reported, particularly with tirzepatide-containing products (Zepbound, Mounjaro). | If severe, persistent, or accompanied by significant abdominal discomfort. |
| Abdominal pain / cramps | Upper or lower GI discomfort, cramping, or pressure. Varies in location and severity. | If severe, sudden, or worsening — especially upper abdominal pain, which may require evaluation. |
| Indigestion / reflux | Acid reflux, heartburn, or general stomach discomfort. More common when lying down. | If worsening or not improving over time. |
| Fatigue | General tiredness or low energy, reported particularly early in treatment. | If severe, persistent, or interfering with daily function. |
| Headache | Reported by some patients, particularly early in treatment. | If severe, sudden, or accompanied by other unusual symptoms. |
| Reduced appetite | Expected effect of GLP-1 receptor agonism; degree varies by individual and medication. | If extreme or preventing adequate nutrition or hydration. |
| Injection-site reactions | Redness, bruising, or tenderness at the injection site. Typically mild. | If signs of infection appear — increasing redness, warmth, swelling, or discharge. |
Side Effects by GLP-1 Medication
GLP-1 and dual GLP-1/GIP medications share a broadly similar side effect profile due to their receptor mechanisms, but the specifics differ. The table below summarizes key characteristics for major GLP-1 medications. Always refer to each medication's official prescribing information for the complete adverse event profile.
| Brand | Active Ingredient | FDA Approved For | Receptor Target | Commonly Reported GI Side Effects |
|---|---|---|---|---|
| Wegovy Online Rx guide |
Semaglutide | Weight management | GLP-1 | Nausea, vomiting, diarrhea, constipation, abdominal pain |
| Ozempic Online Rx guide |
Semaglutide | Type 2 diabetes | GLP-1 | Nausea, vomiting, diarrhea, constipation, abdominal pain |
| Zepbound Online Rx guide |
Tirzepatide | Weight management | GLP-1 + GIP | Nausea, diarrhea, constipation, vomiting, abdominal pain |
| Mounjaro Online Rx guide |
Tirzepatide | Type 2 diabetes | GLP-1 + GIP | Nausea, diarrhea, constipation, vomiting, abdominal pain |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | GLP-1 | Nausea, diarrhea, abdominal pain, constipation, vomiting |
Side effect frequency and severity data are sourced from each medication's FDA prescribing information. Rates differ between clinical trials; individual experience will vary. See official prescribing information for complete adverse event tables.
How Long Do GLP-1 Side Effects Last?
Side effect duration is highly individual and differs between medications. There is no single timeline that applies to all patients. The following reflects general patterns observed in clinical prescribing information — not a prediction for any specific patient.
Early treatment / dose changes: Gastrointestinal side effects — particularly nausea — are most frequently reported when first starting a GLP-1 medication or in the period after a dose change. This pattern appears across prescribing information for semaglutide and tirzepatide products.
As treatment continues: Some patients report that GI side effects diminish as their body adjusts to the medication. Others experience effects that persist throughout treatment. The clinical trials that support these medications included patients who tolerated treatment for extended periods, but individual outcomes vary considerably.
What this means for you: If you are experiencing side effects that concern you, affect your ability to eat or drink, or interfere with daily life, contact your prescriber. Do not change your dose, stop the medication, or restart after a gap without guidance from a licensed clinician. Adjustments to treatment are medical decisions.
Do GLP-1 Medications Cause Hair Loss?
Hair loss — including queries like "does Zepbound cause hair loss" and "does Wegovy cause hair loss" — is among the most-searched side effect topics for GLP-1 medications. Here is what the current evidence suggests.
Hair loss has been reported by some patients using GLP-1 medications, particularly those experiencing significant or rapid weight reduction. The pattern is most consistent with telogen effluvium — a temporary, stress-related form of hair shedding triggered by metabolic or physiological changes rather than a direct drug effect on hair follicles.
Factors that may contribute to hair loss in people using GLP-1 medications:
- Rapid weight reduction (telogen effluvium)
- Significant caloric restriction
- Nutritional changes or deficiencies
- Physiological or metabolic stress
- Pre-existing conditions worsened by dietary change
- Hormonal changes associated with weight loss
GLP-1 medications are not categorized as drugs that directly cause hair loss in their prescribing information, but the metabolic changes they help produce can be a contributing factor for some patients. Hair loss related to rapid weight reduction is typically temporary. If you are concerned about hair loss while using a GLP-1 medication, discuss it with your prescriber — do not start supplements or other interventions without clinician guidance.
Serious Warning Signs: When to Seek Medical Attention
Most GLP-1 side effects are gastrointestinal and manageable with clinician guidance. However, some symptoms warrant prompt medical evaluation. Contact your prescriber or seek emergency care if you experience any of the following.
Severe abdominal pain
Particularly severe, persistent, or worsening pain in the upper abdomen may require prompt evaluation. Do not self-diagnose.
Persistent vomiting
Repeated vomiting or inability to keep fluids down can lead to dehydration and warrants contact with a clinician.
Signs of dehydration
Extreme thirst, dark or infrequent urination, dizziness, light-headedness, or rapid heartbeat may indicate significant dehydration.
Allergic reaction symptoms
Rash, hives, facial swelling, throat tightening, or difficulty breathing require immediate medical attention.
Jaundice or eye yellowing
Yellowing of the skin or whites of the eyes may indicate a liver or gallbladder issue and should be evaluated promptly.
Rapid heartbeat or palpitations
An unusual or rapid heartbeat, especially if accompanied by dizziness or shortness of breath, should be evaluated by a clinician.
Vision changes
Sudden or significant changes in vision should be reported to a clinician promptly — especially in patients with diabetes.
Any severe or unusual symptoms
This list is not exhaustive. Any symptom that feels severe, sudden, or out of the ordinary warrants contact with a licensed clinician or emergency care.
Compounded and Unapproved GLP-1 Products: What the FDA Says
Some patients encounter compounded GLP-1 preparations sold online — often at lower prices and sometimes without a legitimate prescription requirement. The FDA has raised significant safety concerns about these products.
⚠️ FDA Safety Warning on Compounded GLP-1 Products
The FDA has issued multiple warnings and enforcement actions regarding compounded GLP-1 products, including:
- Compounded semaglutide is not a generic version of Ozempic or Wegovy, and is not FDA-approved.
- Compounded tirzepatide is not a generic version of Mounjaro or Zepbound, and is not FDA-approved.
- Dosing errors have been reported with compounded GLP-1 products, including doses significantly higher than intended.
- Inconsistent potency and purity are concerns with products not subject to FDA manufacturing oversight.
- Some products are marketed with misleading claims about equivalence to FDA-approved medications.
- The FDA has issued warning letters to telehealth companies illegally marketing compounded GLP-1 preparations.
Lower price is not an indicator of equivalent safety or efficacy. If you are considering a compounded GLP-1 product, discuss the risks with a licensed clinician first.
For a detailed explanation of the regulatory distinction between FDA-approved GLP-1 medications and compounded alternatives, see our guide: Compounded GLP-1 Medications. For information on why sources claiming no prescription is needed carry additional risk, see: GLP-1 Medications Without a Prescription.
When to Talk With a Licensed Provider
GLP-1 medications are prescription drugs, and questions about side effects — including whether to continue, pause, or adjust treatment — are medical decisions. The checklist below identifies situations where contacting a licensed clinician is appropriate.
- You are experiencing nausea, vomiting, or diarrhea that interferes with eating or drinking
- You have abdominal pain that is severe, persistent, or worsening
- You are having difficulty staying hydrated due to vomiting or diarrhea
- You are noticing hair loss and want to discuss whether it may be related to treatment
- You have started a new medication and want to check for potential interactions
- You are experiencing any symptom that feels severe, sudden, or unusual
- You have questions about whether your current treatment is working or appropriate
- You are considering stopping or pausing your medication
Licensed online GLP-1 programs include clinicians who can review your medical history, address side effect concerns, and determine whether any adjustment is medically appropriate. These programs require medical screening and a legitimate prescription — not just a checkout form.
Learn more about how online GLP-1 prescriptions work, or compare programs that include clinician follow-up care at Best Online GLP-1 Programs.
Explore GLP-1 Medications and Programs
Learn more about specific medications, online programs, cost, eligibility, and safety from our GLP-1 medications hub.
Compare Online GLP-1 Programs With Clinician Support
If you have questions about GLP-1 side effects or want to discuss whether a GLP-1 medication is appropriate for your situation, a licensed online program connects you with a clinician who can review your medical history and, if appropriate, write a prescription through a legitimate pharmacy.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following official sources were used for prescribing information and regulatory guidance referenced on this page. Always verify against the most current version of each document.
-
FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss -
FDA — Wegovy (semaglutide) Prescribing Information 2026
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf -
FDA — Zepbound (tirzepatide) Prescribing Information 2026
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf -
Ozempic (semaglutide) — Prescribing Information
https://www.ozempic.com/prescribing-information.html -
Mounjaro (tirzepatide) — US Prescribing Information (Eli Lilly)
https://pi.lilly.com/us/mounjaro-uspi.pdf -
FDA — Warning Letters to Telehealth Companies Regarding Illegal Marketing of Compounded GLP-1 Medications
https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s